Acute intrauterine pulmonary hypertension impairs endothelium-dependent vasodilation in the ovine fetus.
To determine whether acute pulmonary hypertension in utero alters fetal pulmonary vascular reactivity, we compared pulmonary vasodilation with an endothelium-dependent agonist, acetylcholine, with that of an endothelium-independent agonist, 8-bromo-guanosine 3',5'-cylic monophosphate. Acute pulmonary hypertension was produced in chronically prepared, late-gestation fetal lambs by 3 repeated 30-minute partial occlusions of the ductus arteriosus (DA). The first DA compression increased LPA blood flow from 80 +/- 10 to 180 +/- 21 mL/min (p < 0.01) and decreased pulmonary vascular resistance. In contrast, LPA blood flow did not change and pulmonary vascular resistance increased by 25% during the third period of DA compression. Pulmonary vasodilation during acetylcholine infusion after serial DA compressions was decreased in comparison with the acetylcholine-induced vasodilator response achieved during the baseline period (fall in pulmonary vascular resistance = -49 +/- 7% (baseline) versus -25 +/- 5% after repeated DA compressions; p < 0.05). In contrast, the vasodilator response to 8-bromo-guanosine 3',5'-cylic monophosphate remained intact. To determine whether decreased nitric oxide (NO) production may contribute to altered vasoreactivity after acute pulmonary hypertension, repeated DA compressions were performed after treatment with a nonspecific NO synthase inhibitor (nitro-L-arginine). NO synthase inhibition blocked the pulmonary vasodilation during the first DA compression period, and repeated DA compressions after NO synthase inhibition did not further alter the hemodynamic response to DA compression. These findings support the hypothesis that brief hypertension due to DA compression impairs endothelium-dependent pulmonary vasodilation in the fetus, and that this may be due to decreased NO production.
Storme
L
L
The Service de Medecine Neonatale, Hopital jeanne de Flandre, CHRU de Lille, France.
Rairigh
R L
RL
Parker
T A
TA
Kinsella
J P
JP
Abman
S H
SH
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D002245:Carbon Dioxide / Q000097:blood; D006152:Cyclic GMP / Q000031:analogs & derivatives / Q000494:pharmacology; D004373:Ductus Arteriosus / Q000502:physiology* / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000196:embryology* / Q000502:physiology / Q000503:physiopathology; D005260:Female; D005865:Gestational Age; D006340:Heart Rate, Fetal / Q000187:drug effects / Q000502:physiology; D006439:Hemodynamics; D006976:Hypertension, Pulmonary / Q000196:embryology* / Q000503:physiopathology; D009569:Nitric Oxide / Q000502:physiology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D019335:Nitroarginine / Q000494:pharmacology; D010100:Oxygen / Q000097:blood; D011247:Pregnancy; D011652:Pulmonary Circulation / Q000187:drug effects / Q000502:physiology; D012756:Sheep; D014664:Vasodilation / Q000502:physiology*
D002245:Carbon Dioxide; D019335:Nitroarginine; C016276:8-bromocyclic GMP; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D006152:Cyclic GMP; D000109:Acetylcholine; D010100:Oxygen